Reported Earlier, Travere Therapeutics Wins FDA Approval Of FILSPARI For Focal Segmental Glomerulosclerosis Without Nephrotic Syndrome, Delivering 48% Proteinuria Reduction Vs 27% For Irbesartan In Phase 3 DUPLEX Study
FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndrome
Additional indication for FILSPARI expands total addressable population to more than 100,000 patients in the U.S, including more than 30,000 patients with FSGS
Label aligns with KDIGO clinical practice guidelines for managing patients with FSGS
Login to comment